Optiver Holding
AKBA icon

Optiver Holding’s Akebia Therapeutics AKBA Stock Holding History

Optiver Holding’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2K Sell
8,756
-7,057
-45% -$9.7K ﹤0.01% 1183
2025
Q4 		$25.5K Buy
15,813
+13,629
+624% +$28.5K ﹤0.01% 990
2025
Q3 		$5.96K Buy
+2,184
New +$7.26K ﹤0.01% 1600

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Optiver Holding's AKBA Position: Q1 2026 in Review

Optiver Holding reduced its Akebia Therapeutics (AKBA) stake by 45% in Q1 2026, selling an estimated $9.7K and leaving 8,756 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Optiver Holding first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. The position peaked at $25.5K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Optiver Holding held 8,756 shares of Akebia Therapeutics worth $12.2K as of Q1 2026.
  • Optiver Holding sold 7,057 Akebia Therapeutics shares in Q1 2026, an estimated $9.7K.
  • Akebia Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1183 holding.
  • Optiver Holding first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Akebia Therapeutics position peaked at $25.5K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.